Fallopian tube cancer+1
Not yet recruitingStudy of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6
Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6
- Disease:Fallopian tube cancerOvarian cancer
- Substances:Glatiramer AcetateHUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST CLDN6 CONJUGATED TO MONOMETHYL AURISTATIN E VIA A CATHEPSIN HYDROLYSABLE DIPEPTIDE VC LINKER
Spain- Participants:18–64 years · 65+ years
- Substances:Glatiramer Acetate
- Sponsor:Torl Biotherapeutics LLC








